By Yuting Dun
Holding the Trend of CDMO Services.
As 36Kr team learned, Laviana Pharma. Which company focusing on the Micromolecule Innovative Drugs has captured almost Million RMB, which main from V-Capital and follow by Zhaoyin Wealth, for the Round B+ Investment.
Laviana Pharma. Is established in 2005, was listing on NEEQ in 2016. Later on has capture one million RMB for Round B Investment, which main from Huayi Capital and Jifeng Capital. Now the company has setting branches at Beijing, Tianjin, Taizhou, Cangzhou and USA. Including Management Center, R&D Center, Non-GMP Pilot R&D and Manufacture Facility, as well as the cGMP manufacture Facility. Moreover, company also has oversea sub-company.
So far, Laviana has established an open-type technology platform, it can cover needs of innovative drugs (main is micromolecule) production from lab to industrialization, including pre-clinical to post-marketing process R&D, process optimization, pilot scale test, and so on. The treatment field involving antiviral, antineoplastic, angiocarpy, metabolism system disease, central nervous system disease, etc.
According to Frost&Sullivan, starting from 2007, the pharmaceutical enterprise all over the world is cutting the R&D and production business, then moving to APAC area step by step. The most potential area is China and India. Micromolecule outsourcing business is keeping popularity all the time, also is higher than the increasing level of pharmaceuticals industry. CDMO companies from the mainland of China is seizing the marker because of the cost advantage and service flexibility.
Laviana Pharma. Had already cooperated with more than 200 company from the life science field all over the world, the main clients group is from Europe and America(almost 80%), including top 10 medical tycoon and new-prominent medical companies.
In view of the long chain and many outsourcing link for new drug research, in order to increase the clients viscidity, all the CDMO Company is looking for an integration development, which including developing CRO business, improving business capacity for follow-up CMO business. Moreover, extending to API or preparations is also be used to decreasing risk of clients’ technical transfer.
Mr. Wenting Chen thought, with the development of medical research and design all over the world, multinational pharmaceutical companies’ development is a horizontal development, start from pharmaceutical enterprise changing to therapy enterprise, further transition is the healthy management enterprise, their technical and capacity requirements of outsourcing companies will increasing step by step. With the boost of precision medicine, the requirements for pharmaceutical developments and manufacture is getting more and more strict. Besides, the changing of human spectrum of disease, the division of CDMO will also become subdivided and specification. As for Laviana, it will be a wonderful development opportunity.
Last is the core-management team, CEO Wenting Chen is graduated from Chemistry Engineering major in Tsinghua University, got his master degree major of organic chemistry in New Mexico State University. Before coming back to start up business, he has new drug R&D working experience more than 10 years in pharmaceuticals companies in USA. Co-founder, CSO Frank Yang, Ph.D, has his undergraduate degree from Peking University, and his Ph.D from University of California Owen Branch. He used to working for Professor K.C.Nicolaou in the Scripps Research Institute, for the post-doctoral research. He was working in many American pharmaceuticals companies of new drug R&D department. COO Mr. Hongqing Chen was graduated from Peking University, use to be the assistant of manager and vice plant manager in Jiangyan Chemical Fertilizer LLC. In Jiangsu province. He has more than 10 years’ management experience before the business. The whole team has more than 200 people right now.
This article is excerpts from “Focusing on Micromolecule Innovative Drugs, Providing CDMO Services, Laviana Pharma. Capture almost Million RMB From V-Capital for Round B Investment.” By Yuting Dun, please check the original article link down below.